These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16221807)

  • 1. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection.
    Kpozèhouen A; Alioum A; Anglaret X; Van de Perre P; Chêne G; Salamon R
    Am J Epidemiol; 2005 Mar; 161(6):595-603. PubMed ID: 15746476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some design issues in trials of microbicides for the prevention of HIV infection.
    Fleming TR; Richardson BA
    J Infect Dis; 2004 Aug; 190(4):666-74. PubMed ID: 15272392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 6. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 8. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.
    Bretz F; Maurer W; Hommel G
    Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.
    Howard G; Coffey CS; Cutter GR
    Stroke; 2005 Jul; 36(7):1622-3. PubMed ID: 15947275
    [No Abstract]   [Full Text] [Related]  

  • 11. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 12. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 15. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
    Atkinson AC; Biswas A
    Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sample size for a clinical trial: a Bayesian-decision theoretic approach.
    Halpern J; Brown BW; Hornberger J
    Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial.
    Hiance A; Chevret S; Lévy V
    J Clin Epidemiol; 2009 Apr; 62(4):431-437.e2. PubMed ID: 19010642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ambiguity in a publication: is it a clinical trial or not?].
    Cuena Boy R
    An Med Interna; 2000 Mar; 17(3):160-1. PubMed ID: 10804645
    [No Abstract]   [Full Text] [Related]  

  • 20. Scientists rethink approach to HIV gels.
    Check E
    Nature; 2007 Mar; 446(7131):12. PubMed ID: 17330015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.